GreenSignal Bio Pharma Ltd IPO Message Board (Page 16)

Very very good IPO.

Hi......i m new to this portal. Can anybody tell whether GS ipo is good to apply or not ?

am i right or wrong
only 8330 applicant will get allotment in retail category

@Eagleye/@Septa Sir....please suggest apply or not

What is the gmp??

Grey market price.

/faq/what_is_grey_market/75/

What is a kostak

@ Mitzshah in which city costak is 500.

I want to sell @ 400

BCG Vaccine treats Type 1 Diabetes ??

Bcg prevents tuberculosis, nt treats diabetes

What is the issue size in rupees and no. Of shares?

WHAT IS PRIMUM OFGREENSIGNAL

Being a new investor , Is it viable to invest in green signal , under current scenario as per the expert review growth of pharma industry , Suggest me please ?

if tomorrow pnbhfl list in premium,you should sell it.
gmp some time misguide.

pnbhfl''s mkt value is not in premium

be careful.

What u have to say about PNB HF listing. Listing dekh kar sharam aa rhi hai ya nhi.

Gmp and vyaj??

Apply or avoid in gsbpl

Apply as many as possible

#Allotment

How to ensure at least 1lot from this Ipo as RII subscription expected to be in higherâ„….
I ll apply 2 lots from 2 application.
Any other trick ?
Guys Share ur experience .

Apply as many lots from as many Pan nos

Which next ipo aft green signal comes?

All pharma stocks down on Friday trade:So why invest in this pharma stock

Sunpharma : -7.08%
Dreddy : --5.22%
Auropharma:-3.16%
Lupin : -2.95%

EPS of Rs 1.45 is for 3 months right??? (Pg 64 of RHP)

1. Even though the reported EPS for 2015-16 is Rs.1.45, in actual terms, the company had earned an EPS of Rs.3.90 for 2015-16. Hence the asking price of Rs.80 works out only to a little above 20 PE multiples as against over 30 multiples for Pharma Industry
2. BCG Vaccine need not be treated as single product, as it is existing for the past 100 years. No substitute has been found out so far. So the use of single product company by any one is ignorance.
3. UNICEF''s order to GSBPL till 2018 is only 14% of the total order. As UNICEF''s tender process and GSBPL''s WHO PQ were at the same time, the full potential of GSBPL was not visible. For their lowest quote, GSBPL should have got more quota. We may expect increased requirement from UNICEF for 2017 and 2018 and a better quota for the next 3 year contract commencing from 2019. GSBPL can also quote higher rate during the next contract.
4. Someone has rightly observed that the margins of Serum Institute is around 50% whereas the margins for GSBPL is around 25%. Thus there is ample scope for GSBPL to improve their PAT margin.


Taken from WHO Global TB report 2016

1. Globally only 7.1% of children below 5 years having confirmed TB cases have started TB preventive treatment in 2015. When more children start taking preventive treatment, business potential for GSBPL increases.
2. It is seen that TB cases among adults is going up. Hence more and more countries would make BCG vaccination during child birth compulsory to avoid adult TB cases
3. Of the 30 high TB/HIV burden countries, 21 did not report any provision of preventive treatment in 2015. When such make provision, naturally it will result in increased business for GSBPL.
4. The birth of nearly 230 million children under age 5 worldwide (about 1 in 3) have never been officially recorded. Hence countries will make reporting of child birth compulsory and more kids under 5 can be covered for TB prevention treatment.
5. As per figures released by WHO/UNICEF upto 2015, 170 countries are now tagged to uNICEF. Of this, 7 countries have reported less than 50% coverage, 14 countries reported coverage between 50% and 75%, 31 countries reported coverage between 76% and 90%. Majority of them are African Countries. If all these countries decide to increase their coverage, it is business potential for BCG Vaccine and GSBPL.

6. Instances of TB in Britain are stubbornly high. Now 20000 babies may be at risk, because they have not been immunized. It is becauseof BCG vaccine shortage and no one seems to be keeping track of who has not been given it. Experts warn that could cause huge problems in the years to come. Source http://newsvideo.su

1.      Even though the reported EPS for 2015-16 is Rs.1.45, in actual terms, the company had earned an EPS of Rs.3.90 for 2015-16. Hence the asking price of Rs.80 works out only to a little above 20 PE multiples as against over 30 multiples for Pharma Industry

2.      BCG Vaccine need not be treated as single product, as it is existing for the past 100 years. No substitute has been found out so far. So the use of single product company by any one is ignorance.


3.      UNICEF''s order to GSBPL till 2018 is only 14% of the total order. As UNICEF''s tender process and GSBPL''s WHO PQ were at the same time, the full potential of GSBPL was not visible. For their lowest quote, GSBPL should have got more quota. We may expect increased requirement from UNICEF for 2017 and 2018 and a better quota for the next 3 year contract commencing from 2019. GSBPL can also quote higher rate during the next contract.

4.      Someone has rightly observed that the margins of Serum Institute is around 50% whereas the margins for GSBPL is around 25%. Thus there is ample scope for GSBPL to improve their PAT margin.


Taken from WHO Global TB report 2016

1. Globally only 7.1% of children below 5 years having confirmed TB cases have started TB preventive treatment in 2015. When more children start taking preventive treatment, business potential for GSBPL increases.
2. It is seen that TB cases among adults is going up. Hence more and more countries would make BCG vaccination during child birth compulsory to avoid adult TB cases
3. Of the 30 high TB/HIV burden countries, 21 did not report any provision of preventive treatment in 2015. When such make provision, naturally it will result in increased business for GSBPL.
4. The birth of nearly 230 million children under age 5 worldwide (about 1 in 3) have never been officially recorded. Hence countries will make reporting of child birth compulsory and more kids under 5 can be covered for TB prevention treatment.
5. As per figures released by WHO/UNICEF upto 2015, 170 countries are now tagged to uNICEF. Of this, 7 countries have reported less than 50% coverage, 14 countries reported coverage between 50% and 75%, 31 countries reported coverage between 76% and 90%. Majority of them are African Countries. If all these countries decide to increase their coverage, it is business potential for BCG Vaccine and GSBPL.


6. Instances of TB in Britain are stubbornly high. Now 20000 babies may be at risk, because they have not been immunized. It is becauseof BCG vaccine shortage and no one seems to be keeping track of who has not been given it. Experts warn that could cause huge problems in the years to come. Source http://newsvideo.su

GRAY MARKET PREMIUM KITNA HAI?
PER APPLICATION KITNE ME BIKTI HAI ?

10000 but only seller

other biotech player like biocon is available at 35 pe then why to give 55 pe to this ipo ?

septa ji please tell me the report about this company THE BYKE HOSPITALY